Compare Stocks: APM, MDCX, SCNX, and CTXR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APM Aptorum Group	$0.67 -4.6%	$5.04	$0.60 ▼ $4.47	$4.24M	0.38	57,956 shs	167,078 shs
CTXR Citius Pharmaceuticals	$0.63 +9.0%	$0.59	$0.47 ▼ $2.19	$15.84M	1.03	1.05 million shs	824,282 shs
MDCX Medicus Pharma	$0.27 -0.3%	$0.35	$0.24 ▼ $3.05	$16.96M	0.11	1.81 million shs	700,906 shs
SCNX Scienture	$0.38 -1.1%	$0.39	$0.24 ▼ $2.60	$15.77M	3.26	3.50 million shs	263,626 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APM Aptorum Group	0.00%	0.00%	0.00%	-92.03%	-97.33%
CTXR Citius Pharmaceuticals	-4.41%	-9.47%	+11.67%	-11.61%	-56.28%
MDCX Medicus Pharma	+2.87%	+1.51%	-15.62%	-18.46%	-86.84%
SCNX Scienture	-7.04%	-18.98%	+4.63%	-8.31%	-63.07%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APM Aptorum Group	$0.67 -4.6%	$5.04	$0.60 ▼ $4.47	$4.24M	0.38	57,956 shs	167,078 shs
CTXR Citius Pharmaceuticals	$0.63 +9.0%	$0.59	$0.47 ▼ $2.19	$15.84M	1.03	1.05 million shs	824,282 shs
MDCX Medicus Pharma	$0.27 -0.3%	$0.35	$0.24 ▼ $3.05	$16.96M	0.11	1.81 million shs	700,906 shs
SCNX Scienture	$0.38 -1.1%	$0.39	$0.24 ▼ $2.60	$15.77M	3.26	3.50 million shs	263,626 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APM Aptorum Group	0.00%	0.00%	0.00%	-92.03%	-97.33%
CTXR Citius Pharmaceuticals	-4.41%	-9.47%	+11.67%	-11.61%	-56.28%
MDCX Medicus Pharma	+2.87%	+1.51%	-15.62%	-18.46%	-86.84%
SCNX Scienture	-7.04%	-18.98%	+4.63%	-8.31%	-63.07%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APM Aptorum Group	1.00	Sell	N/A	N/A
CTXR Citius Pharmaceuticals	2.40	Hold	$5.00	694.91% Upside
MDCX Medicus Pharma	2.40	Hold	$9.00	3,260.72% Upside
SCNX Scienture	2.00	Hold	$1.50	294.74% Upside

Current Analyst Ratings Breakdown

Latest APM, MDCX, SCNX, and CTXR Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/19/2026	CTXR Citius Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/19/2026	CTXR Citius Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	MDCX Medicus Pharma	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/28/2026	MDCX Medicus Pharma	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
7/16/2026	APM Aptorum Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/8/2026	MDCX Medicus Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/29/2026	APM Aptorum Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/24/2026	CTXR Citius Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	SCNX Scienture	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/4/2026	APM Aptorum Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APM Aptorum Group	$430K	9.86	N/A	N/A	$2.17 per share	0.31
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	$2.77 per share	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	($0.03) per share	N/A
SCNX Scienture	$430K	36.29	N/A	N/A	$1.56 per share	0.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APM Aptorum Group	-$1.36M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CTXR Citius Pharmaceuticals	-$37.43M	-$1.67	N/A	N/A	N/A	N/A	-59.57%	-34.47%	N/A
MDCX Medicus Pharma	-$35.46M	-$2.46	N/A	N/A	N/A	N/A	-3,137.84%	-263.24%	11/13/2026 (Estimated)
SCNX Scienture	-$41.51M	-$2.10	N/A	N/A	N/A	N/A	-53.51%	-42.47%	11/12/2026 (Estimated)

Latest APM, MDCX, SCNX, and CTXR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q3 2026	CTXR Citius Pharmaceuticals	-$0.36	-$0.34	+$0.02	-$0.34	$5.46 million	N/A
8/13/2026	Q2 2026	SCNX Scienture	-$0.09	-$0.07	+$0.02	-$0.07	$1.96 million	$0.34 million
8/12/2026	Q2 2026	MDCX Medicus Pharma	-$0.1275	-$0.21	-$0.0825	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APM Aptorum Group	N/A	N/A	N/A	N/A	N/A
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
SCNX Scienture	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APM Aptorum Group	N/A	0.78	0.78
CTXR Citius Pharmaceuticals	0.08	0.84	0.40
MDCX Medicus Pharma	N/A	1.57	1.57
SCNX Scienture	0.15	3.04	2.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APM Aptorum Group	3.80%
CTXR Citius Pharmaceuticals	16.88%
MDCX Medicus Pharma	N/A
SCNX Scienture	5.68%

Insider Ownership

Company	Insider Ownership
APM Aptorum Group	63.99%
CTXR Citius Pharmaceuticals	4.99%
MDCX Medicus Pharma	8.10%
SCNX Scienture	21.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APM Aptorum Group	30	6.35 million	2.29 million	Not Optionable
CTXR Citius Pharmaceuticals	20	27.45 million	26.08 million	Optionable
MDCX Medicus Pharma	N/A	63.18 million	58.06 million	N/A
SCNX Scienture	N/A	41.06 million	32.28 million	N/A

APM, MDCX, SCNX, and CTXR Headlines

Recent News About These Companies

Scienture Holdings Reports Q2 2026 Results, Launches REZENOPY™ and Narrows Losses

August 14, 2026 | quiverquant.comQ

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

August 14, 2026 | globenewswire.com

Scienture Holdings Stock Price History

August 12, 2026 | investing.com

Scienture launches Rezenopy as second FDA-approved commercial product

August 12, 2026 | msn.com

SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray

August 12, 2026 | globenewswire.com

Scienture Holdings纳洛酮鼻喷雾剂7月将向美批发商发货

July 28, 2026 | finance.sina.com.cnF

Scienture Holdings stock jumps over 20% pre-market: Here's why

July 10, 2026 | msn.com

SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers

July 9, 2026 | finance.yahoo.com

SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers

July 9, 2026 | globenewswire.com

SCNX Share News Today

July 4, 2026 | uk.investing.com

Scienture Holdings (SCNX) Stock Forecast & Price Target

June 25, 2026 | investing.com

Scienture Holdings Stock Short Interest Report | NASDAQ:SCNX | Benzinga

June 24, 2026 | benzinga.com

SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide

June 18, 2026 | globenewswire.com

Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and Scienture Holdings (SCNX)

June 17, 2026 | theglobeandmail.com

SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team

June 9, 2026 | globenewswire.com

SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC

June 4, 2026 | accessnewswire.comA

SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041

June 2, 2026 | globenewswire.com

Scienture Holdings Announces CFO Resignation, Names Interim Successor

May 29, 2026 | tipranks.com

SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion

May 18, 2026 | globenewswire.com

Scienture Holdings Inc SCNX

May 12, 2026 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM, MDCX, SCNX, and CTXR Company Descriptions

Aptorum Group NASDAQ:APM

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

Citius Pharmaceuticals NASDAQ:CTXR

$0.63 +0.05 (+8.99%)

Closing price 04:00 PM Eastern

Extended Trading

$0.61 -0.02 (-3.18%)

As of 07:55 PM Eastern

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Medicus Pharma NASDAQ:MDCX

$0.27 0.00 (-0.26%)

Closing price 04:00 PM Eastern

Extended Trading

$0.27 0.00 (-0.67%)

As of 07:57 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

Scienture NASDAQ:SCNX

$0.38 0.00 (-1.07%)

Closing price 04:00 PM Eastern

Extended Trading

$0.39 +0.01 (+2.11%)

As of 07:43 PM Eastern

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APM, MDCX, SCNX, and CTXR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APM, MDCX, SCNX, and CTXR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APM, MDCX, SCNX, and CTXR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM, MDCX, SCNX, and CTXR Company Descriptions

Aptorum Group NASDAQ:APM

Citius Pharmaceuticals NASDAQ:CTXR

Medicus Pharma NASDAQ:MDCX

Scienture NASDAQ:SCNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APM, MDCX, SCNX, and CTXR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APM, MDCX, SCNX, and CTXR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APM, MDCX, SCNX, and CTXR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM, MDCX, SCNX, and CTXR Company Descriptions

Aptorum Group NASDAQ:APM

Citius Pharmaceuticals NASDAQ:CTXR

Medicus Pharma NASDAQ:MDCX

Scienture NASDAQ:SCNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools